Authors: Wilding I.R.1; Hardy J.G.2; Sparrow R.A.3; Davis S.S.4; Daly P.B.5; English J.R.5
Source: Pharmaceutical Research, Volume 9, Number 11, November 1992 , pp. 1436-1441(6)
Publisher: Springer
Abstract:
Seven healthy, male volunteers were entered into a randomized, open crossover study of the gastrointestinal transit of two enteric-coated 500-mg naproxen tablets. Two radiolabeled tablets were given to each volunteer on two occasions separated by 7 days, once in the fasted state and once after breakfast. Radiolabeling of tablets was achieved by the incorporation of samarium-152 oxide during manufacture, followed by neutron activation of the tablet to produce the gamma-emitting isotope samarium-153. No loss of tablet integrity was seen in the stomach and all tablets disintegrated in the small intestine. Onset of tablet disintegration was controlled predominantly by gastric emptying. Time in the small intestine prior to tablet disintegration was independent of food intake. Naproxen blood levels with time were consistent with the delayed release of naproxen from the tablets. Overall, transit, disintegration, and absorption were as expected from an enteric-coated tablet.
Keywords: naproxen; enteric-coated tablets; samarium-153; neutron activation; gastrointestinal transit
Language: English
Document Type: Regular paper
Affiliations: 1: Pharmaceutical Profiles Ltd., 2 Faraday Building, Highfields Science Park, Nottingham, England. To whom correspondence should be addressed. 2: Pharmaceutical Profiles Ltd., 2 Faraday Building, Highfields Science Park, Nottingham, England. 3: Department of Human Morphology, Queen's Medical Centre, Nottingham, England. 4: Pharmaceutical Profiles Ltd., 2 Faraday Building, Highfields Science Park, Nottingham, England. Department of Pharmaceutical Sciences, University of Nottingham, England. 5: Syntex Pharmaceuticals Ltd., Maidenhead, England.
Links for this article